Rib-X to Present Data on Delafloxacin at European Congress of Clinical Microbiology and Infectious Diseases

NEW HAVEN, Conn.--(BUSINESS WIRE)--Apr 12, 2010 - Rib-X Pharmaceuticals, Inc., a development-stage antibiotics company with a broad product pipeline based on its innovative discovery platform, today announced that an oral presentation of data for delafloxacin, its lead antibiotic candidate, will be given at the 20th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), April 10-14, in Vienna, Austria by Paul G. Ambrose, Pharm.D, FIDSA, Director, Institute for Clinical Pharmacodynamics, Ordway Research Institute. The presentation at ECCMID includes data from a Phase 2 study, completed in January 2009, which confirmed the appropriate clinical doses of delafloxacin for future clinical studies and demonstrated the efficacy of delafloxacin in complicated skin and structure infections (cSSSI) when compared to tigecycline.


 

Oral Presentation:


 

 


 


  • Abstract #O509: Tuesday, April 13, 2010, 12:06-12:18pm, “Population pharmacokinetics and pharmacokinetic-pharmacodynamic metrics for delafloxacin”, Rubino, et.al., (Lecture Hall I/K)
     


 

About Delafloxacin


 

Delafloxacin is a unique hospital antibiotic that offers both IV and oral versatility with a broad antimicrobial spectrum in areas where today's antibiotics are not fully effective including: methicillin resistant Staphylococcus aureus (MRSA), quinolone-resistant Gram-positives, Gram-negatives and anerobes. Delafloxacin has demonstrated efficacy, safety and tolerability in three Phase 2 clinical studies in approximately 1000 subjects and is Phase 3 ready with a potential 2013 new drug application (NDA) filing.


 

About Rib-X


 

Rib-X Pharmaceuticals, Inc. has an industry-leading pipeline of novel antibiotics targeting multidrug-resistant infections in significant and growing segments of the $25 billion antibiotics market. The Rib-X product portfolio has four core programs including two late-stage product candidates, Delafloxacin and Radezolid, both potential best-in-class antibiotics being developed in market-preferred intravenous and oral formulations for maximum flexibility. The foundation of the Rib-X product portfolio is its proven discovery technology, the Ribosome Antibiotic Binding "RAB™" platform, using Nobel-prize-winning knowledge of ribosomal structure and mechanisms of antibiotic binding to create new chemical classes of antibiotics for a wide range of multidrug-resistant bacterial infections.


 

 


 

 


 


 

Contact: Media/Investor Contact:

The Yates Network

Gina Nugent, 617-460-3579

gina@theyatesnetwork.com


 

 

Posted: April 2010

View comments

Hide
(web3)